`U.S. Patent 10,335,462
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`APOTEX INC.,
`Petitioners
`
`v.
`
`NOVO NORDISK A/S,
`Patent Owner
`______________________
`Case IPR2024-00631
`Patent 10,335,462
`______________________
`
`POWER OF ATTORNEY AND
`DESIGNATION OF LEAD AND BACK-UP COUNSEL
`
`
`
`
`
`IPR2024-00631
`U.S. Patent 10,335,462
`
`
`
`Pursuant to 37 C.F.R. § 42.10(b), Patent Owner Novo Nordisk A/S, hereby
`
`appoints the following practitioners as its attorneys to transact all business in the
`
`United States Patent and Trademark Office associated with the above-captioned
`
`inter partes review, and designate their lead and back-up counsel as follows:
`
`1
`
`
`
`IPR2024-00631
`U.S. Patent 10,335,462
`
`
`
`Lead Counsel
`J. Steven Baughman (Reg. No. 47,414)
`GROOMBRIDGE, WU, BAUGHMAN
`& STONE LLP
`Washington, D.C.
`Tel.: (202)505-5832
`Steve.baughman@groombridgewu.com
`
`Backup Counsel
`Megan Raymond (Reg. No. 72,997)
`GROOMBRIDGE, WU, BAUGHMAN
`& STONE LLP
`Washington, D.C.
`Tel.: (202)505-5878
`Megan.raymond@groombridgewu.com
`
`Michael Milea (Reg. No. 71,863)
`GROOMBRIDGE, WU, BAUGHMAN
`& STONE LLP
`565 5th Avenue, Suite 2900
`New York, NY 10017
`P: (332)-269-0029
`Mike.milea@groombridgewu.com
`
`Joshua Reich (Reg. No. 75,338)
`GROOMBRIDGE, WU, BAUGHMAN
`& STONE LLP
`565 5th Avenue, Suite 2900
`New York, NY 10017
`P: (332)-269-0024
`Joshua.reich@groombridgewu.com
`
`
`
`
`Novo Nordisk A/S hereby appoints additional practitioners associated with
`
`Groombridge, Wu, Baughman & Stone LLP who appear in any future updated
`
`
`
`IPR2024-00631
`U.S. Patent 10,335,462
`mandatory notices, and any attorneys from Groombridge, Wu, Baughman & Stone
`
`LLP admitted pro hac vice in this matter.
`
`The individual signing below has the authority to execute this document on
`
`behalf of Novo Nordisk A/S.
`
`Dated: March 5, 2024
`
`
`
`
`
` Respectfully submitted,
`
`By: _/s/____K. Jones____
`Kathryn Jones
`VP, Chief Counsel IP
`
`for Patent Owner Novo Nordisk A/S
`
`
`
`CERTIFICATE OF SERVICE
`
`IPR2024-00631
`U.S. Patent 10,335,462
`
`It is certified that a copy of the following documents has been served in its
`
`entirety on the patent owner as provided in 37 CFR §42.205:
`
`The copy has been served on March 6, 2024 by causing the aforementioned
`
`document to be electronically mailed to the following attorneys of record for
`
`Petitioner listed below:
`
`John J. Molenda
`Lawrence Kass
`Kyler Doh
`Michael I. Green
`Semaglutide@Steptoe.com
`
`Dated: March 6, 2024
`
`
`
`
`
` Respectfully submitted,
`
`
`
`By: /Sayem Osman/
`Sayem Osman
`
`1
`
`